sucralfate suspension
physicians total care, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. there are no known contraindications to the use of sucralfate.
sucralfate suspension
precision dose inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
teva-sucralfate tablet
teva canada limited - sucralfate - tablet - 1g - sucralfate 1g - protectants
sucralfate tablet
aphena pharma solutions - tennessee, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. there are no known contraindications to the use of sucralfate.
sucralfate- sucralfate tablet
actavis pharma, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets, usp are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate- sucralfate oral suspension
amneal pharmaceuticals llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate- sucralfate oral suspension
atlantic biologicals corp. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate- sucralfate oral suspension
avpak - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate- sucralfate oral suspension
avkare - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate- sucralfate oral suspension
avpak - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.